Know Cancer

or
forgot password

Phase I/II Study Examining Pharmacokinetics, Adverse Events, and Surgically Resected Histopathological Response Utilizing a Dose Escalation Model of Doxorubicin Loaded Drug Eluting Superabsorbent Polymer Microspheres in Surgically Resectable Hepatocellular Carcinoma in Humans


Phase 1/Phase 2
19 Years
N/A
Open (Enrolling)
Both
Hepatocellular Carcinoma

Thank you

Trial Information

Phase I/II Study Examining Pharmacokinetics, Adverse Events, and Surgically Resected Histopathological Response Utilizing a Dose Escalation Model of Doxorubicin Loaded Drug Eluting Superabsorbent Polymer Microspheres in Surgically Resectable Hepatocellular Carcinoma in Humans


Inclusion Criteria:



- Patients diagnosed with surgically resectable hepatocellular carcinoma (HCC)

Type of Study:

Interventional

Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Histopathological correlation with surgically resected tumor

Safety Issue:

No

Principal Investigator

Stephen Chung, MD

Investigator Role:

Study Director

Investigator Affiliation:

University of British Columbia

Authority:

Canada: Health Canada

Study ID:

H08-02833

NCT ID:

NCT01116635

Start Date:

January 2010

Completion Date:

February 2012

Related Keywords:

  • Hepatocellular Carcinoma
  • chemoembolization
  • drug eluting microsphere
  • hepato
  • embolotherapy
  • downstage
  • Carcinoma
  • Carcinoma, Hepatocellular

Name

Location